Citations

Mayo Clinic

Clear

1111 citation(s) found for "Wu, Robin".

Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology
Srinivas, Sandy, Ahmed, Bilawal , An, Yi , Bitting, Rhonda L. , Chapin, Brian F. , D’Amico, Anthony V. , Desai, Neil , Dorff, Tanya B. , Eastham, James A., Farrington, Thomas A., Gao, Xin , Gupta, Shilpa , Karnes, R. Jeffrey, Kishan, Amar U. , Kuettel, Michael, Lee, Daniel , Morgan, Todd M. , Pessoa, Rodrigo Rodrigues , Roach, Mack , Rosenfeld, Stan, Scarpato, Kristen R., Shabsigh, Ahmad , Valicenti, Richard K., Wong, J.K. , Kovách, E, Freedman-Cass, Deborah A., Morgan, Todd M , Robin, Tyler P. , Spratt, Daniel E. , Adra, Nabil , Cheng, Heather H. , Cho, Steve Y. , Ippolito, Joseph E. , Lang, Joshua M. , Lotan, Tamara Levin , McDonald, Andrew, Rais‐Bahrami, Soroush , Szmulewitz, Russell Z , Teply, Benjamin A. , Tward, Jonathan D. , VanderWeele, David James , Kovach, Emily

Journal of the National Comprehensive Cancer Network | November 10, 2025 | Volume: 23 | Issue: 11 | Pages: 469-493

10.6004/jnccn.2025.0052 | PMID 41213253 Get It

The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions for patients with prostate cancer across the disease spectrum. The Guidelines sections included in this article focus on metastatic castration-sensitive prostate cancer (mCSPC), nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). For patients with mCSPC, disease characteristics, such as whether metastases arose synchronously or metachronously and the degree of metastatic burden, impact therapy decisions, including how much treatment intensification is appropriate and when prostate-directed and/or metastasis-directed therapy should be considered. In the mCRPC setting, androgen deprivation therapy is continued with the sequential or concurrent addition of certain androgen receptor pathway inhibitors, chemotherapies, immunotherapies, radiopharmaceuticals, and/or targeted therapies. The NCCN Prostate Cancer Panel emphasizes a shared decision-making approach in all disease settings based on patient preferences, prior treatment exposures, biomarkers, the extent and location of metastases, symptoms, and potential side effects.
Abstract 4366487: Artificial Intelligence-Enabled Electrocardiogram for the Detection of Elevated Filling Pressure in Hypertrophic Cardiomyopathy and Cardiac Amyloidosis
Lerberghe, Robin Van, Servaes, Veerle, Robyns, Tomas , Aelst, Lucas Van , Mangold, Kathryn, Oh, Jae K. , Grogan, Martha, Friedman, Paul A. , Herrmann, Joerg, Janssens, Stefan , Robyns, Tomas , Van Aelst, Lucas N L , Vandenberk, Bert , Jacobs, Johanna, Attia, Zachi I. , Oh, Jae K. , Grogan, Martha , Herrmann, Joerg

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4366487 Get It

Introduction: Diastolic dysfunction is a hallmark of heart failure with preserved ejection fraction, yet echocardiographic grading is challenging in patients with hypertrophic or amyloid cardiomyopathies due to variable structural and functional remodeling. Consequently, there is a need for additional diagnostic tools to identify patients at increased risk of diastolic dysfunction and enhanced filling pressure. Research Question: What is the accuracy of an artificial intelligence (AI)-enabled electrocardiogram (ECG) model to predict diastolic dysfunction in hypertrophic and amyloid cardiomyopathy? Methods: We included patients with diverse phenotypes of hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis and validated Mayo Clinic's AI-enabled ECG model to grade diastolic function (normal: grade 0/1; abnormal: grade 2/3). Echocardiographic analysis of systolic (LVEF) and diastolic function was performed within 14 days of ECG recording. Diastolic function was graded based on E/e’ (>14), left atrial volume index (>34 mL/m2), pulmonary venous atrial reversal flow duration (≥30 ms), and peak tricuspid regurgitation velocity (>2.8 m/s). Filling pressure was considered increased if ≥3 parameters were abnormal, inconclusive if 2 were abnomal, and normal if ≥3 were normal. Echocardiograms with severe mitral regurgitation were excluded. Results: We identified and matched 840 ECGs from non-obstructive HCM patients (n=125, age 58±19y, 70% male), 145 ECGs from obstructive HCM patients (n=29, age 56±18y, 66% male), 225 ECGs from apical HCM patients (n=33, age 66±14y, 61% male), and 382 ECGs from cardiac amyloidosis patients (n=49, age 70±13y, 57% male). The AI-enabled ECG model predicted diastolic dysfunction with an accuracy of 65% (non-obstructive HCM), 67% (obstructive HCM), 65% (apical HCM), and 75% (cardiac amyloidosis), with sensitivities of 94% and 97% for obstructive HCM and cardiac amyloidosis, respectively, and high positive and negative predictive values for cardiac amyloidosis. Systolic dysfunction (LVEF≤40%) was more common in cardiac amyloidosis (29%) than in all HCM patients (5%). Conclusion: The AI-enabled ECG model demonstrates moderate accuracy but high sensitivity for detecting diastolic dysfunction and increased filling pressure, especially in obstructive HCM and cardiac amyloidosis. The AI-enabled ECG is a useful, widely scalable, and low cost tool to identify patients at increased risk for diastolic dysfunction.
Distinct human small intestinal microbiome communities underlie visceral hypersensitivity in a humanized mouse model
Comba, Işın Y. , Sekhon, Prabhjot Kaur , Edwards, Brian S. , Willits, Adam , Shields‐Cutler, Robin , Bellampalli, Shreya S. , Mercado‐Perez, Arnaldo , Tienter, Dennis R., Till, Lisa , Farrugia, Gianrico, Kashyap, Purna , Louwies, Tijs, Mars, Ruben At, Bellampalli, Shreya, Mercado-Perez, Arnaldo, Smith-Edwards, Kristen M , Comba, Isin Y , Louwies, Tijs , Mars, Ruben A. , Xiao, Yang , Linden, David R. , Farrugia, Gianrico , Beyder, Arthur

Journal of Clinical Investigation | October 23, 2025 | Volume: 135 | Issue: 24 | Pages: No page available

10.1172/jci190638 | PMID 41129263 Get It

Patient‐centered and proportionate safety reporting in clinical trials facilitates evidence‐based medicine for the benefit of patients and society: An EHA priority
Plate, Ananda, Thanarajasingam, Gita , Doeswijk, Robin , Dreyling, Martin, Bröckelmann, Paul J. , Bröckelmann, Paul J , El‐Galaly, Tarec Christoffer , Dreyling, Martin

HemaSphere | October 15, 2025 | Volume: 9 | Issue: 10 | Pages: No page available

10.1002/hem3.70239 | PMID 41104378 Get It

Environmental impact of computer-aided diagnosis in colonoscopy: a carbon footprint assessment of a prospective study cohort
Olabintan, Olaolu , Halvorsen, Natalie , Baddeley, Robin , Kudo, Shin-ei, Barua, Ishita , Misawa, Masashi , Hunt, Claire , Nilsen, Jens Aksel , Frigstad, Svein Oskar , Rastogi, Amit, Holme, Øyvind , Gulati, Shraddha , Hassan, Cesare , Hayee, Bu , Mori, Yuichi , Kudo, Shin-ei, Mori, Kensaku , Hunt, Claire, East, James E. , Hassan, Cesare , Kalager, Mette , Løberg, Magnus , Haji, Amyn , Bretthauer, Michael , Mori, Yuichi

Endoscopy | October 7, 2025 | Volume: 58 | Issue: 03 | Pages: 303-309

10.1055/a-2717-8365 | PMID 41056995 Get It

Abstract The environmental impact of computer-aided diagnosis (CADx) in colonoscopy is unknown. The potential to reduce greenhouse gas emissions by limiting unnecessary polypectomies may be offset by emissions associated with CADx devices. We quantified and compared the carbon footprint of colonoscopy with and without CADx. Life-cycle carbon emissions associated with endoscopic snares, polyp traps, histopathology, and CADx devices were estimated using life-cycle assessment software. The effect of CADx was estimated by the carbon dioxide equivalent (CO2e) emissions related to outcomes from a prospective cohort of patients who underwent colonoscopy with optical diagnosis under a leave-in-situ strategy (i.e. rectosigmoid polyps ≤5 mm predicted as non-neoplastic were not removed) with and without CADx assistance. We analyzed 1134 individuals (median age 67 years, 59% male) with 1716 colorectal polyps. Colonoscopy with CADx reduced the number of snares and polyp traps from 567 to 543 (difference: 24) and histopathology submissions from 1343 to 1278 (difference: 65). However, the total carbon footprint increased from 832 kg CO2e (95%CI 815 to 847) without CADx to 946 kg CO2e (95%CI 927 to 965) with CADx, corresponding to an absolute increase of 114 kg CO2e (95%CI 80 to 150) or 0.10 kg CO2e per colonoscopy. Using CADx under a leave-in-situ strategy increased the environmental burden of colonoscopy.
Impact of oncology second opinion consultation on anxiety levels and confidence in the organization.
Sullivan, Molly , Hellard, Sally, Jahanzeb, Mohammad , Leming, Philip D. , Randall, Marcus E. , Guinigundo, Andrew S, Hunt, Jillian M., Reid, Amanda, Smeltzer, Matthew, Zoň, Robin , Barrett, William , Jazieh, Abdul Rahman , Reid, Amanda, Jazieh, Khalid

JCO Oncology Practice | October 7, 2025 | Volume: 21 | Issue: 10_suppl | Pages: 406-406

10.1200/op.2025.21.10_suppl.406 Get It

406 Background: Anxiety is highly prevalent among oncology patients, often arising from uncertainty around diagnosis, treatment options, and prognosis. Elevated anxiety can impair decision-making, reduce treatment adherence, and diminish overall quality of life. Effective second opinion consultations may help mitigate anxiety and increase patients’ confidence in recommending healthcare services to others. Our study evaluates the impact of oncology second opinion (OSO) consultations on anxiety level (AL) and confidence in the organization (CIO) providing the second opinion, i.e., Cincinnati Cancer Advisors (CCA) and Naples Cancer Advisors (NCA). Methods: The study included patients with cancer diagnoses, age ≥18 years, who were served in person for OSO at CCA and NCA. A survey was used before and after consultation, measuring AL (scale 1- 10) and CIO level (scale 1 - 10), assessed by asking patients how likely they would refer loved ones to the organization. After the content and face validation, patients completed the survey anonymously, put it in a sealed envelope, and dropped it in a dedicated box. Data was analyzed using paired t-tests to compare the change from pre- to post-consultation scores. Spearman’s correlation test was used to assess the relation between the changes in AL and CIO. Statistical significance was assessed using an alpha-level of 0.05. Analyses were conducted via R and R Studio (version 2025.5.1.513). Results: Overall, 46 consecutive patients participated (45 completed AL pre and post visit survey and 43 completed the CIO pre and post visit survey). The mean pre-consultation anxiety score was 5.92 (SD = 2.58), and the post-consultation score was 3.87 (SD = 2.10), demonstrating a significant reduction (mean paired difference = -2.05; p < 0.0001). The mean pre-consult CIO was 8.21 (SD = 2.03), increasing to 9.73 post-consultation (SD = 0.53), indicating a significant improvement (mean paired difference = 1.66; p < 0.0001). The correlation between changes in AL and CIO was not statistically significant, which may be attributed to the high baseline CIO scores (ceiling effect) and the small sample size. Conclusions: Oncology second opinion was associated with a marked decrease in patient AL and a significant increase in CIO. The patient survey will continue to recruit additional participants to increase the sample size and explore the correlation between changes in AL and CIO. Studying the downstream impact on patient experience and outcome is warranted.
Classifying hypopneas as obstructive or central can enhance transvenous phrenic nerve stimulation therapy patient selection and outcomes
Dupuy-McCauley, Kara , Javaheri, Shahrokh, Germany, Robin , McKane, Scott , Schwartz, Alan R. , Morgenthaler, Timothy I.

Journal of Clinical Sleep Medicine | September 30, 2025 | Volume: 21 | Issue: 12 | Pages: 2113-2120

10.5664/jcsm.11904 | PMID 41025409 Get It

Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits
Shaw, Vikram R. , Byun, Jinyoung , Thrift, Aaron P. , Zhu, Catherine , Li, Donghui , Kelley, Robin Kate , Bracci, Paige M. , Bucur, Roxana , Knox, J. David, Jalal, Prasun K. , Ghobrial, R. Mark , Nguyen, Mindie H. , Parikh, Neehar D. , Wu, Hui‐Chen , El‐Serag, Hashem, Chang, Ping , Chun, Yun Shin , Gu, Jian , Huff, Chad D. , Rashid, Asif, Hwang, Lu‐Yu, Khaderi, Saira, Roberts, Lewis R. , Hassan, Manal M. , Shaw, Vikram R , Byun, Jinyoung , Thrift, Aaron P , Permuth, Jennifer B , Yuan, Jian-Min , Nguyen, Mindie H , Kim, Richard , Gu, Jian , Kaseb, Ahmed O , McGlynn, Katherine A , Roberts, Lewis R , Parikh, Neehar D , Jalal, Prasun K , Han, Younghun , Hatia, Rikita , Cleary, Sean P. , Lok, Anna S. , Permuth, Jennifer B. , Knox, Jennifer, Singal, Amit G. , Kono, Yuko , Shah, Dimpy P. , Kim, Richard D. , El‐Serag, Hashem B. , Rashid, Asif , Klein, Alison P. , McGlynn, Katherine A. , Amos, Christopher I.

International Journal of Cancer | September 27, 2025 | Volume: 158 | Issue: 5 | Pages: 1193-1203

10.1002/ijc.70136 | PMID 41013983 Get It

Abstract Hepatocellular carcinoma (HCC) mortality is increasing globally, partly due to the growing prevalence of nonviral liver diseases. Genome‐wide association studies (GWAS) have identified genetic variants associated with HCC development. Leveraging GWAS summary statistics and linkage disequilibrium score regression (LDSR), we investigated disease co‐development with hepatitis C virus‐negative (HCV‐negative) HCC to provide unique insights into HCC etiology and prioritize relationships for further causal inquiry. We utilized the LDSR statistical framework to estimate the genetic correlation and heritability between HCV‐negative HCC with 901 epidemiologic, behavioral, and clinical traits from the United Kingdom Biobank (UKBB). First, we set the threshold for observed scale heritability of each trait at 0.02 to ensure reliable inferences with adequate study power. Next, we observed significant positive genetic correlations between HCV‐negative HCC and blood‐based biomarkers of liver injury (ALT, GGT) and allostatic load (including glycated hemoglobin, blood pressure, and total albumin). We also identified a positive genetic correlation between HCV‐negative HCC and diseases associated with metabolic dysfunction‐associated steatotic liver disease (MASLD), including diabetes, hypertension, chronic ischemic heart disease, and others. Taken together, our results help to identify polygenic and pleiotropic signals related to different phenotypic traits associated with HCC and support further exploration of the predictive power of blood‐based biomarkers identified in this study for inferring HCC development among HCV‐negative individuals.
Molecular Breast Imaging and Digital Breast Tomosynthesis for Dense Breast Screening: The Density MATTERS Trial
Hruska, Carrie B. , Hunt, Katie N. , Larson, Nicholas B. , Miller, Patricia A. , Ellis, Richard L. , Shermis, Robin B. , Rauch, Gaiane M. , Conners, Amy Lynn , Spilde, Jeannette Gasal, Semaan, D., Siegal, Emily C. , Zingula, Shannon N. , Mandava, Sabala, Martin, Tamara S., Ahmed, Riffat K., Whaley, Dana H. , Gray, Lacey R., Mehta, Ramila A. , Roll, Rebecca J, O’Connor, Michael K. , Rhodes, Deborah J. , Gasal Spilde, Jeannette, Mandava, Sabala R , Adrada, Beatriz E , Gray, Lacey R , Mehta, Ramila A , Roll, Rebecca J , Redfern, Roberta E , O'Connor, Michael K , Rhodes, Deborah J , Hruska, Carrie B , Larson, Nicholas B , Rauch, Gaiane M , Ahmed, Riffat K., Adrada, Beatriz E. , Redfern, Roberta E.

Radiology | September 23, 2025 | Volume: 316 | Issue: 3 | Pages: No page available

10.1148/radiol.243953 | PMID 40985829 Get It

In women with dense breasts, adding molecular breast imaging to digital breast tomosynthesis (DBT) increased both overall and invasive cancer detection rates, while modestly raising the recall rate compared with DBT alone.
Activity of HOCl-generating e-bandage with clinically available hydrogels against Staphylococcus aureus and Acinetobacter baumannii biofilms
Dağsuyu, Eda , Kies, Paige J. , Karau, Melissa J. , Patel, Robin , Beyenal, Haluk , Kies, Paige , Patel, Robin , Beyenal, H

Microbiology Spectrum | September 18, 2025 | Volume: 13 | Issue: 10 | Pages: No page available

10.1128/spectrum.01762-25 | PMID 40965148 Get It

ABSTRACT Biofilms hinder wound infection healing, making wound infections a healthcare challenge for which innovative treatments are needed. A 1.77 cm 2 electrochemical bandage (e-bandage), which generates the biocide hypochlorous acid (HOCl), has shown promising anti-biofilm activity in vitro , ex vivo , and in vivo . The e-bandage is a three-electrode system operationalized by a hydrogel. In addition to providing a conductive electrolyte for the electrodes, the hydrogel provides a protective barrier for the wound. How different hydrogels impact e-bandage functionality is not completely defined. Here, the in vitro activity of seven clinically available hydrogels (xanthan gum, 3M, Duoderm, Prontosan, Purilon, Skintegrity, and Solosite) was evaluated with 1.77 cm 2 HOCl-generating e-bandages using a potentiostat with a multiplexer in a membrane biofilm model against methicillin-resistant Staphylococcus aureus IDRL-6169 and Acinetobacter baumannii ATCC-17978. When applied with polarized HOCl-producing e-bandages, all evaluated hydrogels except Solosite yielded ≥5.5 log 10 CFU/cm 2 reductions in bacterial quantities after 6 h of treatment, with most being below the detection limit at that time point. Prontosan exhibited antibacterial activity independent of e-bandage. Results of this study inform the selection of clinically available hydrogels that may be suitable for use with a 1.77 cm 2 HOCl-producing e-bandage. IMPORTANCE In this study, it was shown that some clinically available hydrogels, combined with a 1.77 cm 2 HOCl-generating electrochemical bandage, deliver time-dependent antimicrobial activity against methicillin-resistant Staphylococcus aureus and Acinetobacter baumannii biofilms, offering a potential approach to treat wound infections, including those caused by antimicrobial-resistant bacteria.